Skip to main content

Chronic Limb Ischemia

3
Pipeline Programs
1
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Mercator MedSystems
Mercator MedSystemsCA - San Leandro
3 programs
3
Dexamethasone Sodium Phosphate Injection, USP, 4 mg/mLPhase 21 trial
Dexamethasone sodium phosphate injection, USP, 4 mg/mLPhase 21 trial
TemsirolimusPhase 21 trial
Active Trials
NCT02479620Unknown120Est. Mar 2020
NCT02479555Unknown120Est. Aug 2020
NCT02908035Unknown100Est. Sep 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Mercator MedSystemsTemsirolimus
Mercator MedSystemsDexamethasone Sodium Phosphate Injection, USP, 4 mg/mL
Mercator MedSystemsDexamethasone sodium phosphate injection, USP, 4 mg/mL

Clinical Trials (3)

Total enrollment: 340 patients across 3 trials

NCT02908035Mercator MedSystemsTemsirolimus

Temsirolimus Adventitial Delivery to Improve Angiographic Outcomes Below the Knee (TANGO)

Start: Mar 2017Est. completion: Sep 2021100 patients
Phase 2Unknown
NCT02479620Mercator MedSystemsDexamethasone Sodium Phosphate Injection, USP, 4 mg/mL

Lower-Limb Adventitial Infusion of DexaMethasone Via Bullfrog to Reduce Occurrence of Restenosis After Atherectomy (ATX)-Based Revascularization

Start: Jun 2016Est. completion: Mar 2020120 patients
Phase 2Unknown
NCT02479555Mercator MedSystemsDexamethasone sodium phosphate injection, USP, 4 mg/mL

Lower-Limb Adventitial Infusion of DexaMethasone Via Bullfrog to Reduce Occurrence of Restenosis After Percutaneous Transluminal Angioplasty Revascularization

Start: Jan 2016Est. completion: Aug 2020120 patients
Phase 2Unknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.